Sukanya Iyer1, Marwa Ismail1, Benita Tamrazi2, Ashley Margol3, Ramon Correa1, Prateek Prasanna1, Niha Beig1, Ruchika Verma1, Volodymyr Statsevyc4, Anant Madabhushi1, and Pallavi Tiwari1
1Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States, 2Radiology, Children's Hospital Los Angels, Los Angels, CA, United States, 3Hematology, Children's Hospital Los Angels, Los Angels, CA, United States, 4Diagnostic Radiology, Cleveland Clinic Foundation, Cleveland, OH, United States
Synopsis
Genomic
Characterization of Medulloblastoma (MB) has recently identified 4 distinct
molecular subgroups: Sonic Hedgehog (SHH), wingless (WNT), Group 3, and Group
4. These subgroups have shown different clinical behaviours and benefits to
subgroup-specific treatments. We explored the feasibility of a new
gradient-entropy radiomic feature, CoLlAGe, to distinguish molecular sub-types
of MB on Gd-T1w MRI. Our
results using multi-class comparison via one way ANOVA and post-hoc comparison
showed significant differences in CoLlAGe features obtained across molecular sub-types. Our
feasibility results suggest that the CoLlAGe features in different tumor regions observed on
routine Gd-T1w MRI may potentially serve as surrogate markers to non-invasively
characterize molecular sub-types of pediatric MB.
Purpose
Medulloblastoma(MB) is the most common brain tumor in
children1. Aggressive MB frequently requires cranio-spinal
radiation, which also causes significant morbidity in long term survivors. Unfortunately,
it is difficult to accurately determine how aggressive MB is in most patients.
Hence, a ‘one-size-fits-all’ radiation and chemotherapy treatment regimen is
widely adopted, causing children to undergo highly aggressive and in some
cases, inadequate radiation therapy. Genomic characterization of MB has
recently identified 4 distinct molecular subgroups: Sonic Hedgehog (SHH),
wingless (WNT), Group 3, and Group 4.2 These subgroups have shown
different clinical behaviours and benefits to subgroup-specific treatments. For
instance, WNT group is known to have the best prognosis, while Group 3 carries
the worst prognosis with 5-year survival rates of 50%.3 This molecular
categorization is only feasible via an invasive biopsy, which carries severe
risks associated with brain impairment. In this work, we explore the
feasibility of a gradient-entropy based radiomic feature called CoLlAGe4 to
distinguish molecular sub-types of MB. CoLlAGe aims to capture subtle
differences in heterogeneity on a per-voxel basis. CoLlAGe features in previous
studies4 have been found to be over expressed for more heterogeneous
and aggressive pathologies, as compared to the less aggressive phenotypes in
adult brain tumors. Hence, in this work, we hypothesize that CoLlAGe measurements
when captured from the different tumor sub regions, will distinguish between
the 4 molecular sub-types of MB, potentially capturing the underlying
differences in tumor heterogeneity as reflected on a molecular scale.Methods
Our cohort consisted of 40 retrospectively collected studies (age: 3 months to 16.5 years) obtained from the Childrens Hospital of Los Angeles (CHLA). The cohort consisted of N=14 cases for SHH subtype, N=2 cases for WNT sub-type, N=7 cases for Group 3, and N=17 cases for Group 4 sub-type.Our workflow first involved registration of the Gd-T1w sequences with age-wise atlases, followed by harmonizing protocol-specific image intensities to template distributions to account for intensity non-standardness5. Expert delineation of enhancing, and necrotic regions was performed on T1w MRI and of edema region on T2w, and FLAIR. CoLlAGe features were then extracted on a per-pixel basis for every region (edema, tumor necrosis, enhancing tumor, non-enhancing tumor), for each of the MRI protocols. 4 statistics, mean, standard deviation, skewness, and kurtosis, were obtained from the extracted CoLlAGe features for every tumor region. We then performed a statistical experiment that aimed at finding significant differences among the 4 molecular subtypes. A one-way ANOVA test was performed followed by a “multiple comparison of means" Post Hoc test, to identify if the means of any groups have any significant statistical differences across the different subtypes of MB.Results and Discussion
Statistically significant features were found from the enhancing tumor, necrotic core, as well as the non-enhancing tumor regions. In the enhancing tumor region, 2 features- Variance of CoLlAGe differential average (p = 0.0301, Figure 1a) and Variance of CoLlAGe inertia (p= 0.0328) found statistically significant differences between Group 4 and SHH with a 95% confidence interval. We also found statistical differences in the necrotic core between Group 3 and Group 4, as well as group 3 and SHH. The two most significant features were the Skewness of the average sum of CoLlAGe(p = 0.00015, Figure 1b) and Variance of CoLlAGe (p = 0.0016) , both showing differences between Group 3 with SHH and Group 4.We also found that the absolute entropy of the
most aggressive sub-type - Group 3 was the highest in this region. Similarly, significant features were found in the non-enhancing tumor region, which showed differences between SHH and Group 3, as well as SHH and Group 4. The two most significant features included Skewness of CoLlAGe entropy (p= 0.0019, Figure 1c) and energy (p= 0.00128). Conclusion
We presented a novel radiogenomics approach- CoLlAGe, to distinguish between the Wingless, Sonic Hedgehog, Group 3 and Group 4 molecular subtypes of MB on routine T1w protocols. We then employed statistics obtained from the magnitude of these CoLlAGe features in 4 brain regions, to segregate different molecular sub-types of MB. Among SHH, Group 3 and Group 4; we found one molecular sub type to be significant from the others in every brain region (excluding edema).
Clinical Implications
Identifying non-invasive markers on MRI will have therapeutic implications in personalizing treatment management of pediatric MB. While promising, our findings were limited by the small sample size. Acknowledgements
No acknowledgement found.References
[1]
Taran, S., Taran, R., Malipatil, N., and
Haridas, K. Paediatric MB: An updated review. West Indian Med J. 2016 Mar 16;65(2):363-368.
(2016).
[2]
Kool, M., Korshunov, A., Remke, M., and et
al. Molecular subgroups of MB: an international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 MBs.
[3]
Lastowska, M., Trubicka, J.andNiemira, M.,
and et al. MB with transitional features
between Group 3 and Group 4 is associated with good prognosis. J Neurooncol 138: 231 (2018).
[4]
Prasanna, P., Tiwari, P., & Madabhushi, A. (2014). Co-occurrence of
Local Anisotropic Gradient Orientations (CoLlAGe): Distinguishing Tumor
Confounders and Molecular Subtypes on MRI. In Medical Image Computing
and Computer-Assisted Intervention–MICCAI 2014 (pp. 73-80). Springer
International Publishing.
[5] Madabhushi, A.,
&Udupa, J. K. (2006). New methods of MR image intensity standardization via
generalized scale. Medical Physics, 33(9), 3426-3434.